Saltar al contenido
Merck

Decreased parathyroid Klotho expression is associated with persistent hyperparathyroidism after kidney transplantation.

Transplantation proceedings (2013-10-26)
Y A Hong, D E Choi, S W Lim, C W Yang, Y-K Chang
RESUMEN

Although successful kidney transplantation usually corrects hyperparathyroidism, the condition persists in some patients. The present study was designed to determine whether Klotho or fibroblast growth factor 23, the key regulator of parathyroid hormone, is involved in persistent hyperparathyroidism in kidney transplant recipients (KTRs). Nineteen hyperplastic parathyroid glands were obtained from end-stage renal disease (ESRD) patients and KTRs; 6 normal parathyroid glands were used as controls. We compared the expression of Klotho, fibroblast growth factor receptor 1 (FGFR1) and calcium-sensing receptor (CaSR) in the KTRs and ESRD patients. Expressions of Klotho, FGFR1, CaSR and vitamin D receptor, as evaluated by immunohistochemistry, were quantified as the number of positive cells per unit area. The Klotho, FGFR1 and CaSR expressions in parathyroid glands of the post-kidney transplantation (PSKT) and the ESRD groups were significantly decreased compared with normal controls. In the ESRD group, Klotho expression and number of proliferating cell nuclear antigen-positive cells in the parathyroid gland were significantly decreased in parathyroid adenomas as compared with parathyroid hyperplasia. The expression of FGFR1 and CaSR in the parathyroid glands was significantly increased in the PSKT compared with the ESRD group. There was no significant difference in Klotho expression between the PSKT and ESRD groups. Incomplete recovery of Klotho levels in the parathyroid gland may play a role in the pathogenesis of tertiary hyperparathyroidism after kidney transplantation.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
ββ-Glucuronidasa from Helix pomatia, Type HP-2, aqueous solution, ≥100,000 units/mL
Sigma-Aldrich
ββ-Glucuronidasa from Helix pomatia, Type H-2, aqueous solution, ≥85,000 units/mL
Sigma-Aldrich
ββ-Glucuronidasa from Helix pomatia, Type H-1, partially purified powder, ≥300,000 units/g solid
Sigma-Aldrich
β-Glucuronidase from Escherichia coli, Type IX-A, lyophilized powder, 1,000,000-5,000,000 units/g protein (30 min assay)
Sigma-Aldrich
ββ-Glucuronidasa from Helix pomatia, Type H-5, lyophilized powder, ≥400,000 units/g solid
Sigma-Aldrich
ββ-Glucuronidasa from limpets (Patella vulgata), Type L-II, lyophilized powder, 1,000,000-3,000,000 units/g solid
Sigma-Aldrich
ββ-Glucuronidasa from Helix pomatia, Type HP-2S, aqueous solution, ≥90,000 units/mL
Sigma-Aldrich
β-Glucuronidase from Escherichia coli, Type VII-A, lyophilized powder, 5,000,000-20,000,000 units/g protein, pH 6.8 (30 min assay)
Sigma-Aldrich
β-Glucuronidase from bovine liver, Type B-1, ≥1,000,000 units/g solid
Sigma-Aldrich
ββ-Glucuronidasa from Helix pomatia, Type H-3, aqueous solution, ≥90,000 units/mL
Sigma-Aldrich
β-Glucuronidase from Escherichia coli, >20,000,000 units/g protein, recombinant, expressed in E. coli, aqueous glycerol solution
Sigma-Aldrich
β-Glucuronidase from Escherichia coli, ≥20,000 units/mg protein, recombinant, expressed in E. coli overproducing strain, lyophilized powder
Sigma-Aldrich
β-Glucuronidase from Escherichia coli, ≥10,000,000 units/g protein (30 min assay), recombinant, expressed in E. coli overproducing strain, lyophilized powder
Sigma-Aldrich
β-Glucuronidase from Escherichia coli, aqueous glycerol solution, ≥5,000,000 units/g protein, pH 6.8 (biuret)
Sigma-Aldrich
ββ-Glucuronidasa from limpets (Patella vulgata), aqueous solution, ≥85,000 units/mL
Sigma-Aldrich
β-Glucuronidase from bovine liver, Type B-3, ≥2,000,000 units/g solid
Sigma-Aldrich
ββ-Glucuronidasa from Helix pomatia, Type H-3AF, aqueous solution, ≥60,000 units/mL
Sigma-Aldrich
β-Glucuronidase from Helix aspersa (garden snail), Type HA-4